Compare GSK plc (GSK) vs Realty Income Corp (O) Price & Performance

GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.

GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.

Realty Income (O) trades at $65.04, up 1.99% on the day, near its consensus price target of $67.50. The stock shows bullish technical signals with strong moving averages and support at $63. Recent earnings have missed expectations for three consecutive quarters, though revenue grew to $5.75B in 2025. The company maintains a high gross margin of 92.54% and recently expanded its credit facilities to $5.5B, supporting growth initiatives.

Outlook remains cautiously optimistic with 41% analyst buy ratings, but elevated P/E of 51.85 and consistent earnings misses pose valuation risks. Dividend stability and liquidity improvements provide income investor appeal, yet debt levels rising to 39.93% of assets require monitoring. The stock offers steady income but faces pressure to meet earnings forecasts for sustained upside.